Fig. 2

PD-L1 monoclonal antibody atezolizumab alleviates myocardial infarction damagein the breast cancer combined with myocardial infarction model. (A) Comparison of cGAMP levels in the sham, Model, and Model + PD-L1 antibody groups. (B) Masson staining results of myocardial infarction. (C) TTC staining of myocardial infarction damage in each group. (*P < 0.05; **P < 0.01)